Background: Rett syndrome (RTT) is a severe neurodevelopmental disorder that represents the second most common cause of mental retardation in females. However, incidence and prevalence of RTT are scarcely reported. Methods: A retrospective study included all patients with RTT diagnosed between 1981 and 2012 in Serbia. Estimation of incidence and prevalence was calculated on the basis of vital statistics reported by Statistical Office of Republic of Serbia. Results: From 1981 to 2012, RTT has been diagnosed in 102 girls in Serbia. Incidence of RTT in Serbia is estimated at 0.586:10,000 female live births. We estimated the prevalence of RTT in population of females younger than 19 years at 1:8,439. Death occurred in 19 patients (18.63%), with pneumonia as the most common cause. The lethal outcome by the age of 12 years could be expected for 11% of patients. The mean age at diagnosis was 3.5 years and we have confirmed a significant trend towards earlier dianosis during studied period. Conclusions: Rett syndrome incidence in Serbia is in accordance with reports from other countries. Serbian RTT patients have increased risk for early death when compared to patients in more developed countries, most commonly due to pneumonia. There was significant trend towards early diagnosis of RTT in Serbia over recent decades.

Keywords:
Rett syndrome, Incidence, Prevalence, Survival, Diagnosis
1.
Amir RE, Van den Veyver IB, Wan M, et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999;23:185-188.
2.
Hagberg B: Rett syndrome: clinical peculiarities and biological mysteries. Acta Paediatr 1995;84:971-976.
3.
Rett A: On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien Med Wochenschr 1966;116:723-726.
4.
Hagberg B, Aicardi J, Dias K, et al: A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol 1983;14:471-479.
5.
Kerr A, Stephenson JB: A study of the natural history of Rett syndrome in 23 girls. Am J Med Genet Suppl 1986;1:77-83.
6.
Terai K, Munesue T, Hiratani M, et al: The prevalence of Rett syndrome in Fukui prefecture. Brain Dev 1995;17:153-154.
7.
Talvik T, Soot A, Beilmann A, et al: Rett syndrome in Estonia: prevalence of the classical phenotype. Acta Paediatr 1995;84:1070-1071.
8.
Boltshauser E, Kunzle C: Prevalence of Rett syndrome in Switzerland. Helv Paediatr Acta 1987;42:407-411.
9.
Burd L, Vesley B, Martsolf JT, et al: Prevalence study of Rett syndrome in North Dakota children. Am J Med Genet 1991;38:565-568.
10.
Suzuki H, Hirayama Y, Arima M: Prevalence of Rett syndrome in Tokyo. No To Hattatsu 1989;21:430-433.
11.
Skjeldal OH, von Tetzchner S, Aspelund F, et al: Rett syndrome - geographic variation in prevalence in Norway. Brain Dev 1997;19:258-261.
12.
Kozinetz CA, Skender ML, MacNaughton N, et al: Epidemiology of Rett syndrome: a population-based registry. Pediatrics 1993;91:445-450.
13.
Laurvick CL, de Klerk N, Bower C, et al: Rett syndrome in Australia: a review of the epidemiology. J Pediatr 2006;148:347-352.
14.
Bienvenu T, Philippe C, De Roux N, et al: The incidence of Rett syndrome in France. Pediatr Neurol 2006;34:372-375.
15.
Berg M, Hagberg B: Rett syndrome: update of a 25 year follow-up investigation in Western Sweden - sociomedical aspects. Brain Dev 2001;23:S224-S226.
16.
Kerr AM, Armstrong DD, Prescott RJ, et al: Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry 1997;6:71-74.
17.
Freilinger M, Bebbington A, Lanator I, et al: Survival with Rett syndrome: comparing Rett's original sample with data from the Australian Rett Syndrome Database. Dev Med Child Neurol 2010;52:962-965.
18.
Diagnostic criteria for Rett syndrome. The Rett Syndrome Diagnostic Criteria Work Group. Ann Neurol 1988;23:425-428.
19.
Neul JL, Kaufmann WE, Glaze DG, et al; RettSearch Consortium: Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010;68:944-950.
20.
Leonard H, Bower C, English D: The prevalence and incidence of Rett syndrome in Australia. Eur Child Adolesc Psychiatry 1997;6:8-10.
21.
Halbach NS, Smeets EE, van den Braak N, et al: Genotype-phenotype relationships as prognosticators in Rett syndrome should be handled with care in clinical practice. Am J Med Genet A 2012;158A:340-350.
22.
Pozzi CM, Rosemberg S: Rett syndrome: clinical and epidemiological aspects in a Brazilian institution. Arq Neuropsiquiatr 2003;61:909-915.
23.
Fehr S, Bebbington A, Nassar N, et al: Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res 2011;70:313-319.
24.
Hagberg B, Hagberg G: The Swedish Rett syndrome series updated March 1996. Geographical distribution at ages 3-19 years. Eur Child Adolesc Psychiatry 1997;6:12-13.
25.
Wong VC, Li SY: Rett syndrome: prevalence among Chinese and a comparison of MECP2 mutations of classic Rett syndrome with other neurodevelopmental disorders. J Child Neurol 2007;22:1397-1400.
26.
Pini G, Milan M, Zappella M: Rett syndrome in northern Tuscany (Italy): family tree studies. Clin Genet 1996;50:486-490.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.